Treatment initiation in epilepsy: An expert consensus in Spain

Epilepsy and Behavior

Volumn 19, Issue 3, 2010, Pages 332-342

  Villanueva, V ^a   Sanchez Alvarez J C ^b   Pena P ^c   Puig, J Salas ^d   Caballero Martinez F ^e   Gil Nagel, A ^f  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

^b HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

^c HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^d HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^e Teaching and Research Unit   (Spain)

^f HOSPITAL RUBER INTERNACIONAL   (Spain)

Author keywords

Antiepileptic drug; Delphi method; Epilepsy; Initial monotherapy; Start of treatment

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; ESCITALOPRAM; ETHOSUXIMIDE; ETIRACETAM; GABAPENTIN; LAMOTRIGINE; OXCARBAZEPINE; TOPIRAMATE; VALPROIC ACID;

ABSENCE; AGING; ARTICLE; COMORBIDITY; CONSENSUS DEVELOPMENT; ELECTROENCEPHALOGRAPHY; EPILEPSY; EPILEPTIC FOCUS; FEMALE; FOCAL EPILEPSY; GENERALIZED EPILEPSY; HEALTH SURVEY; HUMAN; MALE; MONOTHERAPY; MYOCLONUS EPILEPSY; MYOCLONUS SEIZURE; NUCLEAR MAGNETIC RESONANCE IMAGING; QUESTIONNAIRE; SPAIN; SPIKE WAVE; TONIC CLONIC SEIZURE; TREATMENT INDICATION;

ANTICONVULSANTS; CLINICAL TRIALS AS TOPIC; COMORBIDITY; CONSENSUS; ELECTROENCEPHALOGRAPHY; EPILEPSY; FACULTY, MEDICAL; GUIDELINES AS TOPIC; HUMANS; QUESTIONNAIRES; SPAIN; TREATMENT OUTCOME;

EID: 78649906463     PISSN: 15255050     EISSN: 15255069     Source Type: Journal    
DOI: 10.1016/j.yebeh.2010.07.016     Document Type: Article

References (51)

1. Hauser W.A., Annegers J.F., Kurland L.T. Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota:1935-1984. Epilepsy 1993, 34:453-468.
2. Blume W.T., Lüders H.O., Mizrahi E., Tassinari C., van Emde Boas W., Engel J. Glossary of descriptive terminology for ictal semiology: report of the ILAE task force on classification and terminology. Epilepsy 2001, 42:1212-1218.
3. Fisher R.S., van Emde Boas W., Blume W., et al. Epileptic seizures and epilepsy: definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). Epilepsia 2005, 46:470-472.
4. French J.A., Kanner A.M., Bautista J., et al. Efficacy and tolerability of the new antiepileptic drugs. I. Treatment of new onset epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 2004, 62:1252-1260.
5. Glauser T., Ben-Menachem E., Bourgeois B., et al. ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia 2006, 47:1094-1120.
6. Official guide for the diagnosis and treatment of epilepsy 2008 2008, Spanish Neurology Society Epilepsy Study Group, Prous Science, Barcelona.
7. Andalucian epilepsy guide 2009 2009, Andalucian Epilepsy Society, Editorial EMISA, Madrid.
8. Karceski S., Morrell M., Carpenter D. The expert consensus guideline series: treatment of epilepsy. Epilepsy Behav 2001, 2. (Suppl.):A1-50.
9. Semah F., Picot M.C., Derambure P., et al. The choice of antiepileptic drugs in newly diagnosed epilepsy: a national French survey. Epileptic Disord 2004, 6:255-265.
10. Karceski S., Morrell M.J., Carpenter D. Treatment of epilepsy in adults: expert opinion, 2005. Epilepsy Behav. 2005, 7(Suppl. 1):S1-S64.
11. Wheless J.W., Clarke D.F., Carpenter D. Treatment of pediatric epilepsy: expert opinion, 2005. J Child Neurol 2005, 20(Suppl. 1). S1-56; quiz S59-60.
12. Wheless J.W., Clarke D.F., Arzimanoglou A., Carpenter D. Treatment of pediatric epilepsy: European expert opinion, 2007. Epileptic Disord 2007, 9:353-412.
13. Legros B., Boon P., De Jonghe P., Sadzot B., Van Rijckevorsel K., Schmedding E. Opinion of Belgian neurologists on antiepileptic drug treatment in 2006: Belgian study on epilepsy treatment (BESET-2). Acta Neurol Scand 2009, 120:402-410.
14. Dalkey N.C. The Delphi Method: an experimental study of group opinion 1969, Rand Corp., Santa Monica, CA, Publication RM-59999 PR.
15. Dalkey N., Brown B., Cochran S. The Delphi method: III: Use of self ratings to improve group estimates 1969, Rand Corp., Santa Monica, CA, Publication RM-6115-PR.
16. Goodman L.A. Snowball sampling. Ann Math Statist 1961, 32:148-170.
17. Brook R.H., Chassin M.R., Fink A., Solomon D.H., Kosecoff J., Park R.E. A method for the detailed assessment of the appropriateness of medical technologies. Int J Tech Assess Health Care 1986, 2:53-63.
18. Kahn D.A., Docherty J.P., Carpenter D., Frances A. Consensus methods in practice guideline development: a review and description of a new method. Psychopharmacol Bull 1997, 33:631-639.
19. Beers M.H. Explicit criteria for determining potentially inappropriate medication use by the elderly. Arch Intern Med 1997, 157:1531-1536.
20. Fick D.M., Cooper J.W., Wade W.E., Waller J.L., Maclean J.R., Beers M.H. Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts. Arch Intern Med 2003, 163:2716-2724.
21. Holey E.A., Feeley J.L., Dixon J., Whittaker V.J. An exploration of the use of simple statistics to measure consensus and stability in Delphi studies. BMC Med Res Methodol 2007, 7:52.
22. Almansa C., Rey E., Bolaños E., Palma M., Álvarez A., Díaz-Rubio M. Opinion of Spanish doctors on irritable bowel syndrome: results of a study using the Delphi method. Rev Esp Enferm Dig 2007, 99:210-217.
23. Dago A., Arcos P., Álvarez de Toledo F., Baena M.I., Martínez J., Gorostiza I. Indicadores de riesgo de morbilidad prevenible causada por medicamentos. Gac Sanit 2007, 21:29-36.
24. Leone M.A., Solari A., Beghi E. Treatment of the first tonic-clonic seizure does not affect long-term remission of epilepsy. Neurology 2006, 67:2227-2229. for the FIRST Group.
25. Marson A., Jacoby A., Johnson A., Kim L., Gamble C., Chadwick D., et al. Immediate versus deferred antiepileptic drug treatment for early epilepsy and single seizures: a randomised controlled trial. Lancet 2005, 365:2007-2013.
26. Shinnar S., Berg A.T., O'Dell C., et al. Predictors of multiple seizures in a cohort of children prospectively followed from the time of their first unprovoked seizure. Ann Neurol 2000, 48:140-147.
27. Berg A.T., Shinnar S. The risk of seizure recurrence following a first unprovoked seizure: a quantitative review. Neurology 1991, 41:965-972.
28. Hauser W.A., Rich S.S., Annegers J.F., Anderson V.E. Seizure recurrence after a 1st unprovoked seizure: an extended follow-up. Neurology 1990, 40:1163-1170.
29. Ramsay R.E., Rowan A.J., Pryor F.M. Special considerations in treating the elderly patient with epilepsy. Neurology 2004, 62(Suppl. 2):S24-S29.
30. Ng S.K., Hauser W.A., Brust J.C., Susser M. Hypertension and risk of new-onset unprovoked seizures. Neurology 1993, 43:425-428.
31. Hauser W.A., Rich S.S., Lee J.R., Annegers J.F., Anderson V.E. Risk of recurrent seizures after two unprovoked seizures. N Engl J Med 1998, 338:429-433.
32. Hesdorffer D.C., Logroscino G., Cascino G., Annegers J.F., Hauser W.A. Risk of unprovoked seizure after acute symptomatic seizure: effect of status epilepticus. Ann Neurol 1998, 44:908-912.
33. Morris G.L., Hammer A.E., Kustra R.P., Messenheimer J.A. Lamotrigine for patients with juvenile myoclonic epilepsy following prior treatment with valproate: results of an open-label study. Epilepsy Behav 2004, 5:509-512.
34. Crawford P.M. Managing epilepsy in women of childbearing age. Drug Saf 2009, 32:293-307.
35. Noachtar S., Andermann E., Meyvisch P., Andermann F., Gough W.B., Schiemann-Delgado J., et al. Levetiracetam for the treatment of idiopathic generalized epilepsy with myoclonic seizures. Neurology 2008, 70:607-616.
36. Sazgar M., Bourgeois B.F. Aggravation of epilepsy by antiepileptic drugs. Pediatr Neurol 2005, 33:227-234.
37. Park S.P., Kwon S.H. Cognitive effects of antiepileptic drugs. J Clin Neurol 2008, 4:99-106.
38. Rowan A.J., Ramsay R.E., Collins J.F., et al. New onset geriatric epilepsy: a randomized study of gabapentin, lamotrigine, and carbamazepine. Neurology 2005, 64:1868-1873. for the VA Cooperative Study 428 Group.
39. Zaccara G. Neurological comorbidity and epilepsy: implications for treatment. Acta Neurol Scand 2009, 120:1-15.
40. Kutlu G., Gomceli Y.B., Unal Y., Inan L.E. Levetiracetam monotherapy for late poststroke seizures in the elderly. Epilepsy Behav 2008, 13:542-544.
41. Gilad R., Sadeh M., Rapaport A., et al. Monotherapy of lamotrigine versus carbamazepine in patients with poststroke seizure. Clin Neuropharmacol 2007, 30:189-195.
42. van Breemen M.S., Wilms E.B., Vecht C.J. Epilepsy in patients with brain tumours: epidemiology, mechanisms, and management. Lancet Neurol 2007, 6:421-430.
43. Bhigjee A.I., Rosemberg S. Optimizing therapy of seizures in patients with HIV and cysticercosis. Neurology 2006, 67(Suppl. 4):S19-S22.
44. Mula M., Monaco F. Antiepileptic drugs and psychopathology of epilepsy: an update. Epileptic Disord 2009, 11:1-9.
45. Ahmed S.N., Siddiqi Z.A. Antiepileptic drugs and liver disease. Seizure 2006, 15:156-164.
46. Lacerda G., Krummel T., Sabourdy C., Ryvlin P., Hirsch E. Optimizing therapy of seizures in patients with renal or hepatic dysfunction. Neurology 2006, 67(Suppl. 4):S28-S33.
47. Gidal B.E., French J.A., Grossman P., Le Teuff G. Assessment of potential drug interactions in patients with epilepsy: impact of age and sex. Neurology 2009, 72:419-425.
48. Rocamora R., Sánchez-Álvarez J.C., Salas-Puig J. The relationship between sleep and epilepsy. Neurologist 2008, 14(Suppl. 1):S35-S43.
49. Johannessen Landmark C. Antiepileptic drugs in non-epilepsy disorders: relations between mechanisms of actions and clinical efficacy. CNS Drugs 2008, 22:27-47.
50. Möller J.C., Hamer H.M., Oertel W.H., Rosenow F. Late-onset myoclonic epilepsy in Down's syndrome (LOMEDS). Seizure 2001, 10:303-306.
51. Ben-Menachem E. Weight issues for people with epilepsy: a review. Epilepsia 2007, 48(Suppl. 9):42-45.